Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stake Raised by Fairmount Funds Management LLC
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stake Raised by Fairmount Funds Management LLC
Fairmount Funds Management LLC lifted its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 21.1% during the 1st quarter, HoldingsChannel reports. The fund owned 469,264 shares of the biotechnology company's stock after purchasing an additional 81,864 shares during the period. Enanta Pharmaceuticals accounts for 7.9% of Fairmount Funds Management LLC's portfolio, making the stock its 5th biggest position. Fairmount Funds Management LLC's holdings in Enanta Pharmaceuticals were worth $33,402,000 as of its most recent filing with the Securities & Exchange Commission.
据HoldingsChannel报道,Fairmount Funds Management LLC在第一季度将其在Enanta制药公司(纳斯达克代码:Enta-Get Rating)的股票头寸提高了21.1%。该基金持有这家生物技术公司469,264股,在此期间又购买了81,864股。Enanta PharmPharmticals在Fairmount Funds Management LLC的投资组合中占7.9%,使该股成为其第五大头寸。截至最近提交给美国证券交易委员会的文件,Fairmount Funds Management LLC在Enanta PharmPharmticals持有的股份价值33,402,000美元。
Several other hedge funds have also modified their holdings of ENTA. Signaturefd LLC increased its holdings in shares of Enanta Pharmaceuticals by 86.7% during the 1st quarter. Signaturefd LLC now owns 392 shares of the biotechnology company's stock worth $28,000 after buying an additional 182 shares during the last quarter. Captrust Financial Advisors increased its stake in shares of Enanta Pharmaceuticals by 343.8% during the first quarter. Captrust Financial Advisors now owns 852 shares of the biotechnology company's stock worth $61,000 after acquiring an additional 660 shares during the period. C M Bidwell & Associates Ltd. acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $85,000. KBC Group NV acquired a new position in shares of Enanta Pharmaceuticals during the first quarter worth about $113,000. Finally, Point72 Hong Kong Ltd acquired a new position in shares of Enanta Pharmaceuticals during the fourth quarter worth about $114,000. 97.09% of the stock is owned by hedge funds and other institutional investors.
其他几家对冲基金也调整了对Enta的持股。Signaturefd LLC在第一季度增持了Enanta制药公司的股票86.7%。Signaturefd LLC现在持有这家生物技术公司392股股票,价值2.8万美元,在上个季度又购买了182股。CapTrust Financial Advisors在第一季度将其在Enanta制药公司的股份增加了343.8%。CapTrust Financial Advisors在此期间额外购买了660股,现在拥有852股这家生物技术公司的股票,价值6.1万美元。C M Bidwell&Associates Ltd.在第四季度收购了Enanta制药公司价值约85,000美元的新股票头寸。KBC Group NV在第一季度收购了价值约11.3万美元的Enanta制药公司股票的新头寸。最后,Point72 Hong Kong Ltd在第四季度收购了价值约11.4万美元的Enanta PharmPharmticals股票。97.09%的股票由对冲基金和其他机构投资者持有。
Enanta Pharmaceuticals Price Performance
Enanta制药价格表现
Shares of NASDAQ ENTA traded down $0.98 on Monday, hitting $63.06. The company's stock had a trading volume of 5,707 shares, compared to its average volume of 239,682. Enanta Pharmaceuticals, Inc. has a 12-month low of $37.59 and a 12-month high of $102.00. The company has a market capitalization of $1.31 billion, a price-to-earnings ratio of -10.73 and a beta of 0.55. The stock has a 50 day moving average of $59.75 and a 200-day moving average of $58.66.
周一,纳斯达克恩塔的股价下跌0.98美元,至63.06美元。该公司股票的成交量为5,707股,而其平均成交量为239,682股。Enanta PharmPharmticals,Inc.的12个月低点为37.59美元,12个月高位为102.00美元。该公司市值13.1亿美元,市盈率为-10.73倍,贝塔系数为0.55。该股的50日移动均线切入位在59.75美元,200日移动均线切入位在58.66美元。
Analyst Ratings Changes
分析师评级发生变化
A number of brokerages have recently issued reports on ENTA. SVB Leerink boosted their price target on shares of Enanta Pharmaceuticals from $44.00 to $50.00 and gave the stock a "market perform" rating in a research note on Monday, August 1st. Royal Bank of Canada decreased their price objective on shares of Enanta Pharmaceuticals from $67.00 to $66.00 and set a "sector perform" rating on the stock in a report on Tuesday, August 9th. Evercore ISI raised shares of Enanta Pharmaceuticals from an "in-line" rating to an "outperform" rating and set a $62.00 price objective on the stock in a report on Wednesday, July 6th. Oppenheimer boosted their price objective on shares of Enanta Pharmaceuticals from $53.00 to $59.00 and gave the stock a "market perform" rating in a report on Wednesday, August 10th. Finally, Robert W. Baird decreased their price objective on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an "outperform" rating on the stock in a report on Thursday, May 19th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, Enanta Pharmaceuticals presently has a consensus rating of "Moderate Buy" and an average price target of $78.63.
多家券商近期发布了有关Enta的报告。SVB Leerink在8月1日周一的一份研究报告中将Enanta PharmPharmticals的股票目标价从44.00美元上调至50.00美元,并给出了该股的“市场表现”评级。加拿大皇家银行在8月9日(星期二)的一份报告中将埃南塔制药的股票目标价从67.00美元下调至66.00美元,并对该股设定了“行业表现”评级。Evercore ISI在7月6日(星期三)的一份报告中将Enanta PharmPharmticals的股票评级从“在线”上调至“表现优于大盘”,并为该股设定了62.00美元的目标价。奥本海默在8月10日(星期三)的一份报告中将Enanta制药公司的股票目标价从53.00美元上调至59.00美元,并给予该股“市场表现”评级。最后,罗伯特·W·贝尔德在5月19日星期四的一份报告中将埃南塔制药公司的股票目标价从130.00美元下调至90美元,并对该股设定了“跑赢大盘”的评级。四名分析师对该股的评级为持有,五名分析师对该公司的评级为买入。根据MarketBeat的数据,Enanta PharmPharmticals目前的共识评级为“中等买入”,平均目标价为78.63美元。
Enanta Pharmaceuticals Profile
Enanta制药公司简介
(Get Rating)
(获取评级)
Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.
Enanta制药公司是一家生物技术公司,发现和开发用于治疗病毒感染和肝病的小分子药物。其研发的疾病靶标包括呼吸道合胞病毒、SARS-CoV-2、人类偏肺病毒和乙肝病毒。该公司与雅培签订了一项合作开发和许可协议,以识别、开发和商业化丙型肝炎病毒NS3和NS3/4A蛋白酶抑制剂化合物,包括用于治疗慢性丙型肝炎病毒的paritaprevir和glecapvir。
Featured Stories
专题报道
- Get a free copy of the StockNews.com research report on Enanta Pharmaceuticals (ENTA)
- 3 Downgraded Must-Have Stocks To Put On Your Watchlist
- This Is What To Expect From The Q3 Earnings Reporting Season
- 3 Biotech Stocks Gaining Momentum
- Can Electronic Arts Buck the Downturn in Videogaming?
- Dollar General is the Big Fish in Little Ponds Across the U.S.
- 免费获取StockNews.com关于Enanta制药公司(Enta)的研究报告
- 3只被降级的必备股票放在你的观察名单上
- 这是对第三季度收益报告季节的预期
- 3只生物科技股势头强劲
- 电子艺界能扭转电子游戏市场的低迷吗?
- 美元将军是美国小池塘里的大鱼。
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating).
想看看其他对冲基金持有Enta的股份吗?访问HoldingsChannel.com以获取Enanta制药公司(纳斯达克:Enta-Get Rating)的最新13F备案文件和内幕交易信息。
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
接受Enanta制药日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Enanta制药和相关公司的最新新闻和分析师评级的每日简要摘要。